# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Benchmark analyst Robert Wasserman reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $8 price target.
Emergent BioSolutions has secured over $250 million in contract modifications from the ASPR at the U.S. Department of Health an...
Benchmark analyst Robert Wasserman reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $8 price target.
Benchmark analyst Robert Wasserman reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $8 price target.
Benchmark analyst Robert Wasserman reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $8 price target.
On Thursday prior to the market open, Emergent BioSolutions announced it entered into a definitive agreement with Bora to sell ...
Benchmark analyst Robert Wasserman maintains Emergent BioSolutions (NYSE:EBS) with a Buy and raises the price target from $5...